ClinVar Miner

Submissions for variant NM_031885.5(BBS2):c.224T>G (p.Val75Gly)

gnomAD frequency: 0.00001  dbSNP: rs121908174
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
First Genomix Gene Laboratory, Genetic Diagnostics Department RCV005411280 SCV006079715 pathogenic Bardet-Biedl syndrome 2; Retinitis pigmentosa 74 2025-01-05 criteria provided, single submitter clinical testing As part of Carrier Screening testing performed at First Genomix, this variant was identified in a heterozygous state in a patient who is not affected with this condition.
Baylor Genetics RCV000004831 SCV004213996 likely pathogenic Bardet-Biedl syndrome 2 2023-10-05 criteria provided, single submitter clinical testing
Labcorp Genetics (formerly Invitae), Labcorp RCV001002877 SCV001586209 pathogenic Bardet-Biedl syndrome 2023-12-30 criteria provided, single submitter clinical testing This sequence change replaces valine, which is neutral and non-polar, with glycine, which is neutral and non-polar, at codon 75 of the BBS2 protein (p.Val75Gly). This variant is present in population databases (rs121908174, gnomAD 0.0009%). This missense change has been observed in individuals with clinical features of Bardet-Biedl syndrome (PMID: 11285252, 28143435, 31456290). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 4569). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt BBS2 protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects BBS2 function (PMID: 20498079). For these reasons, this variant has been classified as Pathogenic.
Sharon lab, Hadassah-Hebrew University Medical Center RCV001002877 SCV001160910 pathogenic Bardet-Biedl syndrome 2019-06-23 no assertion criteria provided research
Counsyl RCV000004831 SCV000796082 likely pathogenic Bardet-Biedl syndrome 2 2017-12-08 no assertion criteria provided clinical testing This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com.
OMIM RCV000004831 SCV000025007 pathogenic Bardet-Biedl syndrome 2 2001-04-01 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. The submitted information has not been verified. If you have questions about the information contained on this website, please see a health care professional.